MCID: HPT021
MIFTS: 75

Hepatitis

Categories: Gastrointestinal diseases, Infectious diseases, Rare diseases, Liver diseases, Immune diseases, Genetic diseases

Aliases & Classifications for Hepatitis

MalaCards integrated aliases for Hepatitis:

Name: Hepatitis 37 12 72 28 51 40 14 69
Chronic Persistent Hepatitis 12 51 69
Acute Hepatitis 12 28 69
Hepatitis, Chronic 41 69
Acute and Subacute Liver Necrosis 12
Acute/subac. Necrosis of Liver 12
Chronic Hepatitis 12
Hepatitis Chronic 51
Hepatitis, Animal 69
Animal Hepatitis 12
Hepatitis a 69

Classifications:



Summaries for Hepatitis

MedlinePlus : 40 Your liver is the largest organ inside your body. It helps your body digest food, store energy, and remove poisons. Hepatitis is an inflammation of the liver. Viruses cause most cases of hepatitis. The type of hepatitis is named for the virus that causes it; for example, hepatitis A, hepatitis B or hepatitis C. Drug or alcohol use can also cause hepatitis. In other cases, your body mistakenly attacks healthy cells in the liver. Some people who have hepatitis have no symptoms. Others may have Loss of appetite Nausea and vomiting Diarrhea Dark-colored urine and pale bowel movements Stomach pain Jaundice, yellowing of skin and eyes Some forms of hepatitis are mild, and others can be serious. Some can lead to scarring, called cirrhosis, or to liver cancer. Sometimes hepatitis goes away by itself. If it does not, it can be treated with drugs. Sometimes hepatitis lasts a lifetime. Vaccines can help prevent some viral forms.

MalaCards based summary : Hepatitis, also known as chronic persistent hepatitis, is related to hepatitis a and viral hepatitis, and has symptoms including lameness, animal, gastrointestinal gas and pruritus. An important gene associated with Hepatitis is HAVCR1 (Hepatitis A Virus Cellular Receptor 1), and among its related pathways/superpathways are Kaposi's sarcoma-associated herpesvirus infection and NF-kappaB Signaling. The drugs Aluminum hydroxide and Aluminum sulfate have been mentioned in the context of this disorder. Affiliated tissues include liver, t cells and testes.

Wikipedia : 72 Hepatitis is inflammation of the liver tissue. Some people have no symptoms whereas others develop... more...

Related Diseases for Hepatitis

Diseases in the Hepatitis family:

Hepatitis C Virus Autoimmune Hepatitis
Hepatitis B Hepatitis a
Hepatitis C Viral Hepatitis
Hepatitis D Hepatitis E

Diseases related to Hepatitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1831)
# Related Disease Score Top Affiliating Genes
1 hepatitis a 34.0 AFP GPT HAVCR1 HAVCR2 IFNA2 TNF
2 viral hepatitis 33.5 AFP GPT IFNA1 IFNA2 SEPSECS TNF
3 hepatitis b 33.3 AFP GPT IFNA1 IFNA2 LAMTOR5 NR5A2
4 hepatitis c 33.0 AFP CD81 CLDN1 CLDN6 CLDN9 GPT
5 hepatitis c virus 32.9 CD81 CLDN1 CLDN6 CLDN9 GPT HAVCR2
6 liver disease 32.9 AFP GPT IFNA1 SEPSECS TNF
7 cryoglobulinemia, familial mixed 31.2 IFNA1 IFNA2
8 cholangitis 30.9 CLDN1 GPT TNF
9 acquired immunodeficiency syndrome 30.2 IFNA1 IFNA2 TNF
10 opisthorchiasis 29.8 AFP GPT
11 gastrointestinal system disease 29.7 AFP IFNA1 TNF
12 kaposi sarcoma 29.4 IFNA1 IFNA2 TNF
13 autoimmune hepatitis 12.4
14 hepatic veno-occlusive disease 12.4
15 hepatitis d 12.4
16 hepatic venoocclusive disease with immunodeficiency 12.3
17 alcoholic hepatitis 12.3
18 hepatic encephalopathy 12.3
19 hepatic lipase deficiency 12.3
20 hepatitis e 12.3
21 congenital hepatic fibrosis 12.2
22 renal-hepatic-pancreatic dysplasia 12.2
23 polycystic kidney disease 4 with or without hepatic disease 12.2
24 non-a-e hepatitis 12.2
25 hepatic adenomas, familial 12.2
26 porphyria, acute hepatic 12.1
27 epstein-barr virus hepatitis 12.1
28 hepatic fibrosis, severe due to schistosoma mansoni infection 12.1
29 granulomatous hepatitis 12.0
30 renal-hepatic-pancreatic dysplasia 2 12.0
31 hepatic coma 12.0
32 infections, recurrent, with encephalopathy, hepatic dysfunction, and cardiovascular malformations 12.0
33 drug-induced hepatitis 12.0
34 hepatic flexure cancer 12.0
35 renal-hepatic-pancreatic dysplasia 1 12.0
36 hepatic tuberculosis 12.0
37 fulminant viral hepatitis 12.0
38 hepatic infarction 11.9
39 hepatic angiomyolipoma 11.9
40 halothane hepatitis 11.9
41 hepatitis b vaccine, response to 11.9
42 sclerosing hepatic carcinoma 11.9
43 hepatic vascular disease 11.9
44 hepatocellular carcinoma 11.8
45 primary hepatic neuroendocrine carcinoma 11.8
46 coach syndrome 11.8
47 acute liver failure 11.8
48 isolated congenital hepatic fibrosis 11.8
49 glycogen storage disease iv 11.8
50 chronic end-stage hepatitis c 11.7

Comorbidity relations with Hepatitis via Phenotypic Disease Network (PDN): (show all 16)


Active Peptic Ulcer Disease Acute Cystitis
Acute Kidney Failure Acute Pancreatitis
Cholangitis Chronic Myocardial Ischemia
Deficiency Anemia Esophagitis
Familial Atrial Fibrillation Heart Disease
Hepatic Encephalopathy Hypothyroidism
Ischemic Heart Disease Mitral Valve Disease
Portal Hypertension Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Hepatitis:



Diseases related to Hepatitis

Symptoms & Phenotypes for Hepatitis

UMLS symptoms related to Hepatitis:


lameness, animal, gastrointestinal gas, pruritus, nausea and vomiting, icterus, heartburn, fever, dyspepsia, diarrhea, constipation, abdominal pain, hepatocellular jaundice, hepatosplenomegaly

Drugs & Therapeutics for Hepatitis

Drugs for Hepatitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 789)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aluminum hydroxide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 21645-51-2
2
Aluminum sulfate Approved Phase 4,Phase 3,Phase 1,Phase 2 10043-01-3
3
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
4
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 104987-11-3 445643 439492
5
Emtricitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 143491-57-0 60877
6
Adefovir Dipivoxil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 142340-99-6 60871
7
Entecavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 142217-69-4 153941
8
Peginterferon alfa-2b Approved Phase 4,Phase 3,Phase 2,Phase 1 215647-85-1, 99210-65-8
9
Ribavirin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 36791-04-5 37542
10
Isoniazid Approved, Investigational Phase 4,Phase 3,Phase 2 54-85-3 3767
11
Pyrazinamide Approved, Investigational Phase 4,Phase 2,Phase 3 98-96-4 1046
12
Rifampin Approved Phase 4,Phase 2,Phase 3,Phase 1 13292-46-1 5381226 5458213
13
Neomycin Approved, Vet_approved Phase 4 1404-04-2 8378
14
Peginterferon alfa-2a Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 198153-51-4 5360545
15
Lamivudine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 134678-17-4 60825
16
Telbivudine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 3424-98-4 159269
17
Orlistat Approved, Investigational Phase 4 96829-58-2 3034010
18
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
19
Metformin Approved Phase 4,Phase 2,Phase 3,Phase 1 657-24-9 4091 14219
20
Pioglitazone Approved, Investigational Phase 4,Phase 3,Phase 2 111025-46-8 4829
21
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 93-14-1 3516
22
Methadone Approved Phase 4,Phase 3,Phase 2,Phase 1 76-99-3 4095
23
Ritonavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 155213-67-5 392622
24
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Early Phase 1 83-43-2 6741
25
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Early Phase 1 50-24-8 5755
26
Amantadine Approved Phase 4,Phase 3,Phase 2 768-94-5 2130
27
Dopamine Approved Phase 4,Phase 3,Phase 2 51-61-6, 62-31-7 681
28
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 2 128794-94-5 5281078
29
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2 24280-93-1 446541
30
Ledipasvir Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 1256388-51-8 67505836
31
Sofosbuvir Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 1190307-88-0 45375808
32
Ethiodized oil Approved, Investigational Phase 4,Phase 3,Phase 2 8008-53-5
33
Benzocaine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 1994-09-7, 94-09-7 2337
34
Nitazoxanide Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 55981-09-4 41684
35
Pentoxifylline Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 6493-05-6 4740
36
Chlorhexidine Approved, Vet_approved Phase 4 55-56-1 2713 9552079
37
Ursodeoxycholic acid Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 128-13-2 31401
38
Caspofungin Approved Phase 4 162808-62-0, 179463-17-3 2826718 468682
39
Simvastatin Approved Phase 4,Phase 3,Phase 1 79902-63-9 54454
40
Insulin Glargine Approved Phase 4 160337-95-1
41
Insulin-glulisine Approved Phase 4 207748-29-6
42
Zinc Approved, Investigational Phase 4,Phase 2,Phase 3 7440-66-6 32051 23994
43
Acamprosate Approved, Investigational Phase 4 77337-76-9 71158
44
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1 64-17-5 702
45
Thrombin Approved, Investigational Phase 4,Phase 3,Phase 1
46
Simeprevir Approved Phase 4,Phase 3,Phase 2,Phase 1 923604-59-5 66576988
47
Prednisone Approved, Vet_approved Phase 4,Phase 2,Phase 3 53-03-2 5865
48
rituximab Approved Phase 4,Phase 2,Phase 3,Phase 1 174722-31-7 10201696
49
Thymalfasin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 62304-98-7
50 Simethicone Approved Phase 4,Phase 3

Interventional clinical trials:

(show top 50) (show all 4168)

# Name Status NCT ID Phase Drugs
1 A Randomized,Parallel-group Clinical Trial of Hepatitis B Vaccine With Different Dosages and Schedules in Healthy Adults Unknown status NCT02203357 Phase 4
2 PCV13 + Hepatitis A Vaccine for Adults Unknown status NCT01926860 Phase 4
3 Phase Ⅳ Clinical Trial of Recombinant Hepatitis E Vaccine(Hecolin®) Unknown status NCT02189603 Phase 4
4 Combination Hepatitis A and B Vaccine to Induce Immunity in Non-responders Unknown status NCT01126853 Phase 4
5 Hepatitis C in Renal Transplant Recipients Unknown status NCT02108301 Phase 4 tacrolimus-cyclosporine A
6 Adolescents' Response to Hepatitis B Vaccine Booster Dose Unknown status NCT01341275 Phase 4
7 Emtricitabine for Naive Chinese Pregnant Chronic Hepatitis B Patients Unknown status NCT02327702 Phase 4 Emtricitabine
8 Efficacy Optimizing Research of Chronic Hepatitis B Patients With Inadequate Response to NUC Therapy Unknown status NCT01341743 Phase 4 Entecavir;Entecavir, Adefovir;Entecavir, Adefovir
9 Pegylated Interferon Alfa-2b Plus Ribavirin in Chronic Hepatitis B and Delta Unknown status NCT00117533 Phase 4 pegylated IFN alfa-2b plus ribavirin
10 Hepatitis B Virus (HBV) Antibody (Anti-HBs) Booster Program for the Production of Hepatitis B Immune Globulin (HBIG) Unknown status NCT01311674 Phase 4
11 Reintroduction Regimens After Hepatitis During Anti-tuberculosis Treatment Unknown status NCT01395654 Phase 4 isoniazid, rifampin, pyrazinamide
12 Cellular Immunity in Adult Hepatitis B-vaccinated Serologic Non-responders Unknown status NCT01451801 Phase 4
13 Using Entecavir to Reduce Hepatitis in Highly Viremic HBV Patients During Anti-tuberculous Treatment Unknown status NCT01724723 Phase 4 entecavir (BARACLUDE®)
14 Entecavir for Chronic Hepatitis B Patients With Persistently Normal ALT Unknown status NCT01833611 Phase 4 Entecavir;placebo
15 Sustained Off-treatment Response After HBeAg Loss in Chronic Hepatitis B Patients Treated With Nucleos(t)Ide Analogues Unknown status NCT01911156 Phase 4 Continue NA treatment;Discontinue NA Treatment
16 Effects of Short-term Atorvastatin Treatment on Vaccination Efficacy in Nonresponder Persons to Hepatitis B Vaccine Unknown status NCT01548326 Phase 4 Atorvastatin;placebo
17 Emtricitabine for Naive Child Chinese Chronic Hepatitis B Patients Unknown status NCT02327676 Phase 4 Emtricitabine
18 Influence of Hepatic Steatosis on the Therapeutic Effect of Entecavir in Chronic Hepatitis B Patients Unknown status NCT01148576 Phase 4 entecavir;entecavir;essentiale + entecavir;Vitamin E + entecavir
19 Pegasys Plus Entecavir Versus Entecavir Alone for Hepatitis Be Antigen-Positive Chronic Hepatitis B Unknown status NCT00597259 Phase 4 Pegasys plus Entecavir;Entecavir
20 Emtricitabine for Naive Chinese Chronic Hepatitis B Patients Unknown status NCT02327663 Phase 4 Emtricitabine
21 Efficacy and Safety of S-adenosyl-L-methionine in Treatment of Chronic Hepatitis B Patients With Cholestasis Unknown status NCT01998620 Phase 4 Ademetionine 2;Ademetionine 1;Ademetionine 3
22 Antiviral Efficacy of the Combination Treatment With Poly IC and Entecavir for Chronic Hepatitis B Unknown status NCT02532413 Phase 4 Poly IC;Entecavir
23 The Clinical Trial of the Anti Hepatitis B Placenta Transfer Factor Injection Unknown status NCT02412319 Phase 4 Anti-HBV placenta transfer factor injection
24 Comparison of Telbivudine Plus Adefovir With Lamivudine Plus Adefovir for the Treatment of Lamivudine-resistant Chronic Hepatitis B at 52 Weeks: A Pilot Study Unknown status NCT01804387 Phase 4 telbivudine plus adefovir;lamivudine plus adefovir
25 Hansenula-derived Pegylated Interferon in Treatment of Patients With Chronic Hepatitis C Unknown status NCT01649245 Phase 4 Reiferon retard
26 Switch From Adefovir to Tenofovir in Chronic Hepatitis B for Suboptimal Response to Adefovir-based Combination Therapy Unknown status NCT01595633 Phase 4 Switching from adefovir (10mg/day) to tenofovir (300mg/day)
27 Efficacy of Switching or Adding Pegylated Interferon in Chronic Hepatitis B Patients on Long Term Oral Antiviral Therapy Unknown status NCT01928511 Phase 4 peg-interferon alpha 2b, 1.5mcg/kg s/c given weekly;Nucleos(t)ide analogue therapy
28 Add Vitamin D With Standard of Care for Chronic Hepatitis C Patients Unknown status NCT01439776 Phase 4
29 Efficacy and Safety of S-adenosyl-l-methionine in Treatment of Alcoholic Hepatitis With Cholestasis Unknown status NCT02024295 Phase 4 Ademethionine;Polyene Phosphatidyl choline;Ademethionine
30 Pegylated-Interferon and Ribavirin in Hepatitis C Patients With Persistently Normal Alanine Aminotransferase Levels Unknown status NCT00575627 Phase 4 Peg-Interferon alpha2a plus Ribavirin
31 Efficacy and Safety of Daclatasvir Plus Asunaprevir in Chronic Hepatitis C Unknown status NCT02639585 Phase 4 Daclinza and Sunvepra
32 Increasing Cure Rate of Hepatitis C Therapy in Obese Hepatitis C Patients Unknown status NCT00871845 Phase 4 Orlistat
33 Combination or Sequential Therapy of Peginterferon Alfa-2a and Entecavir for Patients With Chronic Hepatitis B Unknown status NCT01906580 Phase 4 Peg-IFNα-2a;Entecavir
34 A Trial To Study The Effect Of Lamivudine In Adult Patients Who Suffer From Chronic Hepatitis B Alone Unknown status NCT00354653 Phase 4 LAMIVUDINE
35 Compare Continuing Lamivudine Plus Adefovir or Adefovir Versus Switching to Entecavir Plus Adefovir in Patients With LAM-resistant Chronic Hepatitis B Unknown status NCT02482272 Phase 4 Lamivudine;Adefovir;Entecavir
36 Lamivudine Extending Therapy in Chronic Hepatitis B Patients After 3-year of Oral Antiviral Agents Unknown status NCT02337127 Phase 4 Lamivudine
37 Safety and Efficacy of Telbivudine on Liver Cirrhosis in Patients With Chronic Hepatitis B (CHB) Unknown status NCT01380951 Phase 4 telbivudine
38 Treatment of Liver Cirrhosis Due to Hepatitis B Virus With Fuzheng Huayu and Entecavir Unknown status NCT02241590 Phase 4 Entecavir + Placebo;Entecavir + Fuzheng Huayu Tablet
39 Active Drug Comparative Trial to Evaluate the Antiviral Activity and Safety in Chronic Hepatitis B Patients Unknown status NCT02588937 Phase 4 EntecaBell ODT. 0.5mg;Baraclude Tab. 0.5mg
40 Study of Effects and Safety Between Adefovir Dipivoxil Plus Polyene Phosphatidylcholine Versus Adefovir Dipivoxil Alone in Chronic Hepatitis B Patients Unknown status NCT01436539 Phase 4 Adefovir Dipivoxil and polyene phosphatidylcholine;Adefovir Dipivoxil
41 The Effects of Oral Hypoglycemic Agents on Chronic Hepatitis C Patients Receiving Peg-Intron Plus Ribavirin Unknown status NCT01025765 Phase 4 Pioglitazone;Acarbose;Metformin
42 A Pilot Study to Assess the Efficacy and Safety of Folic Acid and/or Vitamin B Complex on Hepatitis C Infected Patients Treated With Pegylated Interferon and Ribavirin. Unknown status NCT02150291 Phase 4 Neurobion;placebo
43 Safety and Efficacy Study Comparing Raltegravir to a Protease Inhibitor in Treatment-naïve, HIV/Hepatitis C Drug Users Unknown status NCT01105611 Phase 4 Raltegravir;Atazanavir/Ritonavir
44 Peginterferon Plus Ribavirin for Hepatitis C Patients Concomitant With Hepatocellular Carcinoma Unknown status NCT00834860 Phase 4 peginterferon alpha-2a and ribavirin
45 Entecavir Plus Tenofovir Combination in Subjects With Multi-drug Resistant Chronic Hepatitis B Virus Infection Unknown status NCT01594905 Phase 4 Entecavir + Tenofovir (MDR group)
46 Prednisolone Priming Study in Patients With Chronic Hepatitis B Unknown status NCT00778596 Phase 4 Prednisolone;Placebo priming
47 Peginterferon Alfa-2a, Ribavirin, Amantadine/Placebo in Hepatitis C Virus (HCV)-Genotype-1-Infection (PRAMA) Unknown status NCT00127777 Phase 4 Amantadine sulphate (in addition to standard treatment)
48 Entecavir and Pegasys Sequential Therapy Versus Pegasys for HBeAg Positive Chronic Hepatitis B Unknown status NCT00921180 Phase 4 Entecavir and peginterferon alfa-2a;Placebo and peginterferon
49 Entecavir and Pegasys Sequential Therapy Versus Pegasys for HBeAg Negative Chronic Hepatitis B Unknown status NCT00917761 Phase 4 Entecavir and peginterferon (Pegasys) (52 weeks);Peginterferon (Pegasys) (96 weeks);Peginterferon (Pegasys) (48 weeks)
50 Improved Prevention of Perinatal Hepatitis B Transmission Unknown status NCT01133184 Phase 4

Search NIH Clinical Center for Hepatitis

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Hepatitis cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Hepatitis:
Promethera
Embryonic/Adult Cultured Cells Related to Hepatitis:
Adult liver progenitor cells PMIDs: 22525602 23211283 19091822 24142276 22900053

Cochrane evidence based reviews: hepatitis, chronic

Genetic Tests for Hepatitis

Genetic tests related to Hepatitis:

# Genetic test Affiliating Genes
1 Acute Hepatitis 28
2 Hepatitis 28

Anatomical Context for Hepatitis

MalaCards organs/tissues related to Hepatitis:

38
Liver, T Cells, Testes, Kidney, Bone, Brain, B Cells

Publications for Hepatitis

Articles related to Hepatitis:

(show top 50) (show all 27074)
# Title Authors Year
1
Models to Predict Hepatitis B Virus Infection Among Patients With Cancer Undergoing Systemic Anticancer Therapy: A Prospective Cohort Study. ( 29447061 )
2018
2
Implementation of hepatitis B birth dose vaccination a89 worldwide, 2016. ( 29450989 )
2018
3
Substitution of amino acid residue V1213 in the helicase domain of the genotype 3 hepatitis E virus reduces virus replication. ( 29422085 )
2018
4
Benign recurrent intrahepatic cholestasis (BRIC)-like episode associated with ATP8B1 variation underlying protracted cholestatic course of acute hepatitis E virus infection. ( 29191380 )
2018
5
Epidemiological data for hepatitis D in Africa - Authors' reply. ( 29241612 )
2018
6
Melatonin attenuates smoking-induced hyperglycemia via preserving insulin secretion and hepatic glycogen synthesis in rats. ( 29437243 )
2018
7
Prediction of Hepatic Encephalopathy: Why disregard well known risk factors? ( 29377250 )
2018
8
Chronic Hepatitis E in a Renal Transplant Recipient: The First Report of Genotype 4 Hepatitis E Virus Caused Chronic InfectionA in Organ Recipient. ( 29432746 )
2018
9
Complete response of diffuse large B-cell lymphoma after direct-acting antiviral therapy for hepatitis C virus. ( 29432921 )
2018
10
Effect of tenofovir on renal function in patients with chronic hepatitis B. ( 29443737 )
2018
11
Correction: An ImmunoSignature test distinguishes Trypanosoma cruzi, hepatitis B, hepatitis C and West Nile virus seropositivity among asymptomatic blood donors. ( 29389963 )
2018
12
Unravelling the fate of functional PD1+ T cells in chronic viral hepatitis. ( 29309052 )
2018
13
Improving Quality of Care for People with Hepatic Encephalopathy. ( 29411992 )
2018
14
Severe steatosis induces portal hypertension by systemic arterial hyporeactivity and hepatic vasoconstrictor hyperreactivity in rats. ( 29326427 )
2018
15
Pathogenicity of duck hepatitis A virus type 3 and innate immune responses of the ducklings to virulent DHAV-3. ( 29407574 )
2018
16
Epidemiological data for hepatitis D in Africa. ( 29241610 )
2018
17
Contrast uptake in primary hepatic angiosarcoma on gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging in the hepatobiliary phase. ( 29399290 )
2018
18
Training in emerging advances in chronic hepatitis C infection in Pakistan: the Teach - Pak project. ( 29445310 )
2018
19
Gastrointestinal and Hepatic Disease in Sjogren Syndrome. ( 29149922 )
2018
20
Hepatitis B virus genotypes A1, A2 and E in Cape Verde: Unequal distribution through the islands and association with human flows. ( 29447232 )
2018
21
An outbreak of acute hepatitis A among young adult men: clinical features and HIV coinfection rate from a large teaching hospital in Rome, Italy. ( 29380498 )
2018
22
Long-term observation of acute-onset autoimmune hepatitis presenting clinically and radiologically as acute hepatitis. ( 29450869 )
2018
23
Tuberculosis and viral hepatitis infection in Eastern Europe, Asia, and Latin America: impact of tumor necrosis factor-I+ inhibitors in clinical practice. ( 29391775 )
2018
24
A case of Kaposi varicelliform eruption progressing to herpes simplex virus hepatitis in an immunocompetent patient. ( 29446473 )
2018
25
Baicalin reverses the impairment of synaptogenesis induced by dopamine burden via the stimulation of GABA<sub>A</sub>R-TrkB interaction in minimal hepatic encephalopathy. ( 29404643 )
2018
26
Hepatitis A and hepatitis B vaccination coverage among adults with chronic liver disease. ( 29395521 )
2018
27
Immunization of preterm infants with GSK's hexavalent combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine: A review of safety and immunogenicity. ( 29336924 )
2018
28
Protective effects of Punica granatum (pomegranate) peel extract on concanavalin A-induced autoimmune hepatitis in mice. ( 29428670 )
2018
29
HAVCR1 (CD365) and its mouse ortholog are functional hepatitis A virus (HAV) cellular receptors that mediate HAV infection. ( 29437974 )
2018
30
Adherence and perceived barriers to oral antiviral therapy for chronic hepatitis B. ( 29447614 )
2018
31
Metagenomic analysis reveals Hepatitis A virus in suspected yellow fever cases in Brazil. ( 29211109 )
2018
32
Induction of genotype-cross reactive, hepatitis C virus-specific cell mediated immunity in DNA-vaccinated mice. ( 29437963 )
2018
33
Is drug-induced hepatitis related to the severity of tuberculous meningitis? ( 29438557 )
2018
34
Autoimmune hepatitis as a complication of common variable immunodeficiency. ( 29368942 )
2018
35
Aiming at the Global Elimination of Viral Hepatitis: Challenges Along the Care Continuum. ( 29354656 )
2018
36
Autoimmune Hepatitis in Children. ( 29446799 )
2018
37
Impaired T cell-mediated hepatitis in peroxisome proliferator activated receptor alpha (PPARI+)-deficient mice. ( 29448959 )
2018
38
Is Interferon-Based Treatment of Viral Hepatitis C Genotype 3 Infection Still of Value in the Era of Direct-Acting Antivirals? ( 29443655 )
2018
39
Disrupted Brain Intrinsic Networks and Executive Dysfunction in Cirrhotic Patients without Overt Hepatic Encephalopathy. ( 29422882 )
2018
40
The disseminated intravascular coagulation score is a novel predictor for portal vein thrombosis in cirrhotic patients with hepatitis B. ( 29178991 )
2018
41
Effect of probiotic treatment on cirrhotic patients with minimal hepatic encephalopathy: A meta-analysis. ( 29428113 )
2018
42
Association of interleukin (IL)-4 variable number of tandem repeats (VNTRs) and IL-4-590 promoter polymorphisms with susceptibility to pediatric autoimmune hepatitis type 1. ( 29396050 )
2018
43
Plant-derived antivirals against hepatitis c virus infection. ( 29439720 )
2018
44
Early liver transplantation for alcoholic hepatitis: Ready for primetime? ( 29175244 )
2018
45
Management of chronic viral hepatitis in the hematological patient. ( 29415584 )
2018
46
Quantitative assessment of HLA-DQ gene polymorphisms with the development of hepatitis B virus infection, clearance, liver cirrhosis, and hepatocellular carcinoma. ( 29416599 )
2018
47
Cytomegalovirus associated longitudinally extensive transverse myelitis and acute hepatitis in an immunocompetent adult. ( 29396069 )
2018
48
Hepatic veno-occlusive disease during isavuconazole administration. ( 29278102 )
2018
49
Prevalence of Hepatitis B virus and Hepatitis D virus coinfection in Western Burkina Faso and molecular characterization of the detected virus strains. ( 29432880 )
2018
50
Interaction between the patatin-like phospholipase domain-containing protein 3 genotype and coffee drinking and the risk for acute alcoholic hepatitis. ( 29404510 )
2018

Variations for Hepatitis

Copy number variations for Hepatitis from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 226111 7 55054218 55242525 Amplification EGFR Hepatitis

Expression for Hepatitis

Search GEO for disease gene expression data for Hepatitis.

Pathways for Hepatitis

Pathways related to Hepatitis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.98 IFNA1 IFNA2 LAMTOR5 TNF
2 11.77 HAVCR1 HAVCR2 IFNA1 TNF
3
Show member pathways
11.64 IFNA1 IFNA2 TNF
4 11.34 CD81 CLDN1 CLDN6 CLDN9 IFNA1 IFNA2

GO Terms for Hepatitis

Cellular components related to Hepatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 bicellular tight junction GO:0005923 8.8 CLDN1 CLDN6 CLDN9

Biological processes related to Hepatitis according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 viral process GO:0016032 9.56 CD81 CLDN1 CLDN6 CLDN9 HAVCR1 LMBRD1
2 humoral immune response GO:0006959 9.5 IFNA1 IFNA2 TNF
3 T cell activation involved in immune response GO:0002286 9.49 IFNA1 IFNA2
4 positive regulation of peptidyl-serine phosphorylation of STAT protein GO:0033141 9.48 IFNA1 IFNA2
5 positive regulation of chemokine production GO:0032722 9.46 HAVCR2 TNF
6 natural killer cell activation involved in immune response GO:0002323 9.43 IFNA1 IFNA2
7 cell-cell junction organization GO:0045216 9.43 CLDN1 CLDN6 CLDN9
8 negative regulation of glucose import GO:0046325 9.4 LMBRD1 TNF
9 protein localization to lysosome GO:0061462 9.37 CD81 LAMTOR5
10 calcium-independent cell-cell adhesion via plasma membrane cell-adhesion molecules GO:0016338 9.33 CLDN1 CLDN6 CLDN9
11 viral entry into host cell GO:0046718 9.1 CD81 CLDN1 CLDN6 CLDN9 HAVCR1 SCARB1

Molecular functions related to Hepatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.26 IFNA1 IFNA2 IFNL4 TNF
2 type I interferon receptor binding GO:0005132 9.16 IFNA1 IFNA2
3 virus receptor activity GO:0001618 9.1 CD81 CLDN1 CLDN6 CLDN9 HAVCR1 SCARB1

Sources for Hepatitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....